RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Advanced Oncotherapy Stock

Advanced Oncotherapy Stocks 2024

Advanced Oncotherapy Stocks

382.48 M

Ticker

AVO.L

ISIN

GB00BD6SX109

WKN

A2AL9X

In 2024, Advanced Oncotherapy had 382.48 M outstanding stocks, a 0% change from the 382.48 M stocks in the previous year.

The Advanced Oncotherapy Stocks history

YEARNUMBER OF STOCKS (undefined GBP)
2027e382.48
2026e382.48
2025e382.48
2024e382.48
2023e382.48
2022e382.48
2021382.48
2020288.98
2019211.48
2018150.54
201777.83
201660.8
201551.28
201434.02
201316.1
20127.06
20113.08
20103.08
20093.08
20083.08
20073.16
20062.95
20052.83
20043.08

Advanced Oncotherapy shares outstanding

The number of shares was Advanced Oncotherapy in 2023 — This indicates how many shares 382.479 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Advanced Oncotherapy earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Advanced Oncotherapy's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Advanced Oncotherapy’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Advanced Oncotherapy's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Advanced Oncotherapy Aktienanalyse

What does Advanced Oncotherapy do?

Advanced Oncotherapy PLC is a therapeutic company in London specializing in the development of advanced and precise radiation therapy solutions. The company was founded in 2005 and has since developed a revolutionary technology that allows for the treatment of cancer cells with the highest precision and minimal to no damage to surrounding tissue. The business model of Advanced Oncotherapy aims to offer innovative technology solutions that benefit patients throughout their medical cancer treatment. The various facets of the company include research and development, production, sales and distribution, as well as clinical trials. Advanced Oncotherapy focuses on a direct customer-customer relationship by offering customers interesting treatment options tailored to the patient's needs. The flagship product of Advanced Oncotherapy is the LIGHT radiation therapy system, which is unique worldwide due to its precision, accuracy, and effectiveness in the treatment of cancer. This system allows oncologists and radiologists to perform innovative radiation therapy that promises better treatment outcomes. The LIGHT technology is based on the principles of intensity-modulated radiation therapy (IMRT) and next-generation particle therapy (NGPT). By using proton beams, the radiation therapy can be focused directly on a specific region of the body where cancer tissue is spreading. Advanced Oncotherapy offers a wide range of radiation therapy services to its customers. This includes proton accelerators (PROTON), PET/CT systems (positron emission tomography/computed tomography), CT scanners (computed tomography), and other tools and devices. The product line has been specifically developed for the precise irradiation of tumors as well as the diagnosis of cancer and other related diseases. Customers of Advanced Oncotherapy are primarily hospitals, medical centers, and health authorities. In recent years, Advanced Oncotherapy has collaborated closely with various partners such as CERN (European Organization for Nuclear Research), the Royal Marsden Hospital, University College London, and other institutions to constantly improve and further develop its technology and products. Milestones in the company's history include the CE marking for the LIGHT system and support for clinical trials by research-intensive university hospitals. The future of Advanced Oncotherapy looks promising, with a strong growth forecast for the global radiation therapy market. With an increasing demand for innovative solutions in cancer treatment, the company can look forward to a growing customer base and an increasing number of partnerships and collaborations. Advanced Oncotherapy will continue to focus on continuously optimizing its technology to provide cancer patients with the best treatment options. Advanced Oncotherapy ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Advanced Oncotherapy's Shares Outstanding

Advanced Oncotherapy's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Advanced Oncotherapy’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Advanced Oncotherapy’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Advanced Oncotherapy’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Advanced Oncotherapy stock

How many stocks are there of Advanced Oncotherapy?

The current number of stocks of Advanced Oncotherapy is 382.48 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Advanced Oncotherapy are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Advanced Oncotherapy evolved in recent years?

The number of shares of Advanced Oncotherapy has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Advanced Oncotherapy as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Advanced Oncotherapy?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Advanced Oncotherapy pay?

Over the past 12 months, Advanced Oncotherapy paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Advanced Oncotherapy is expected to pay a dividend of 0 GBP.

What is the dividend yield of Advanced Oncotherapy?

The current dividend yield of Advanced Oncotherapy is .

When does Advanced Oncotherapy pay dividends?

Advanced Oncotherapy pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Advanced Oncotherapy?

Advanced Oncotherapy paid dividends every year for the past 0 years.

What is the dividend of Advanced Oncotherapy?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Advanced Oncotherapy located?

Advanced Oncotherapy is assigned to the 'Health' sector.

Wann musste ich die Aktien von Advanced Oncotherapy kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Advanced Oncotherapy from 9/17/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.

When did Advanced Oncotherapy pay the last dividend?

The last dividend was paid out on 9/17/2024.

What was the dividend of Advanced Oncotherapy in the year 2023?

In the year 2023, Advanced Oncotherapy distributed 0 GBP as dividends.

In which currency does Advanced Oncotherapy pay out the dividend?

The dividends of Advanced Oncotherapy are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Advanced Oncotherapy

Our stock analysis for Advanced Oncotherapy Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Advanced Oncotherapy Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.